Trial Profile

A Phase 1, Open-Label, Dose Escalation and Expansion Study of ASP1012, an Oncolytic Virus, in Participants With Locally Advanced or Metastatic Solid Tumors

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 08 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ASP 1012 (Primary) ; Pembrolizumab (Primary)
Indications Colorectal cancer; Gastric cancer; Malignant melanoma; Oesophageal cancer; Ovarian cancer; Solid tumours
Focus Adverse reactions; First in man
Sponsors Astellas Pharma Global Development; KaliVir Immunotherapeutics

Most Recent Events

29 May 2026 Actual primary completion date changed from 10 Sep 2025 to 11 Sep 2025.
04 Nov 2025 Status changed from active, no longer recruiting to discontinued. Reason the study was stopped: Due to strategic decision made by the sponsor the study was terminated
07 Aug 2025 Planned End Date changed from 30 Jun 2029 to 28 Feb 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com